{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:15:54Z","timestamp":1765808154432,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.02.057","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T02:06:45Z","timestamp":1677118005000},"page":"2184-2197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A randomized phase I\/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452"],"prefix":"10.1016","volume":"41","author":[{"given":"Eline A.","family":"Feitsma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yester F.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrikus H.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"van Sleen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"van Baarle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Alleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thillainaygam","family":"Sathiyaseelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylaja","family":"Murikipudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea R.","family":"Delpero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie M.","family":"Scully","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramya","family":"Ragupathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sravya","family":"Kotha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishit J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhya","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashikant","family":"Nagre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon E.","family":"Ronca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freedom M.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Aminetzah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans","family":"Sollie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schelto","family":"Kruijff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Brom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gooitzen M.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Zion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.vaccine.2023.02.057_b0005","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMe2025111","article-title":"The Covid-19 vaccine-development multiverse","volume":"383","author":"Heaton","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2023.02.057_b0010","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1007\/s12035-021-02399-6","article-title":"A review on SARS-CoV-2-induced neuroinflammation, neurodevelopmental complications, and recent updates on the vaccine development","volume":"58","author":"Karnik","year":"2021","journal-title":"Mol Neurobiol"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.057_b0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.057_b0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"6499","key":"10.1016\/j.vaccine.2023.02.057_b0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.02.057_b0030","unstructured":"Organization, W.H., Status of COVID-19 Vaccines within WHO EUL\/PQ evaluation process. WHO Guidance Document, 2021. May 18th, 2021."},{"key":"10.1016\/j.vaccine.2023.02.057_b0035","unstructured":"Thompson MG et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep 2021;70(13): 495-500."},{"key":"10.1016\/j.vaccine.2023.02.057_b0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: the COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.057_b0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10249","key":"10.1016\/j.vaccine.2023.02.057_b0050","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10267","key":"10.1016\/j.vaccine.2023.02.057_b0055","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.057_b0060","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.02.057_b0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"45","key":"10.1016\/j.vaccine.2023.02.057_b0070","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1016\/j.vaccine.2021.09.077","article-title":"Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452","volume":"39","author":"Alleva","year":"2021","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2023.02.057_b0075","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.vaccine.2022.01.043","article-title":"Phase I interim results of a phase I\/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452","volume":"40","author":"Janssen","year":"2022","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.057_b0080","doi-asserted-by":"crossref","first-page":"e81587","DOI":"10.1371\/journal.pone.0081587","article-title":"A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines","volume":"8","author":"Du","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2023.02.057_b0085","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.4049\/jimmunol.174.8.4908","article-title":"Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies","volume":"174","author":"He","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.02.057_b0090","doi-asserted-by":"crossref","unstructured":"Loureiro S et al. Virus Glycoproteins Tagged with the Human Fc Domain as Second Generation Vaccine Candidates. Innovation in Vaccinology: From Design, Through to Delivery and Testing, 2012. Chapter 3.","DOI":"10.1007\/978-94-007-4543-8_3"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.057_b0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41392-022-01185-7","article-title":"An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants","volume":"7","author":"Luo","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2023.02.057_b0100","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41423-021-00658-z","article-title":"Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice","volume":"18","author":"Sun","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2023.02.057_b0105","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.vaccine.2008.11.083","article-title":"Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen","volume":"27","author":"Zhang","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.057_b0110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.057_b0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2023.02.057_b0120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.vaccine.2023.02.057_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2020.113995","article-title":"Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2","volume":"287","author":"Park","year":"2021","journal-title":"J Virol Methods"},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.057_b0130","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial","volume":"22","author":"Oosting","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.02.057_b0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.057_b0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.vaccine.2023.02.057_b0145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"2 Suppl","key":"10.1016\/j.vaccine.2023.02.057_b0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4269\/ajtmh.2011.09-0516","article-title":"Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51","volume":"84","author":"Herrera","year":"2011","journal-title":"Am J Trop Med Hyg"},{"issue":"43","key":"10.1016\/j.vaccine.2023.02.057_b0155","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1016\/j.vaccine.2008.07.034","article-title":"Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants","volume":"26","author":"Qiu","year":"2008","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2023.02.057_b0160","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1128\/IAI.73.6.3587-3597.2005","article-title":"Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial","volume":"73","author":"Oliveira","year":"2005","journal-title":"Infect Immun"},{"issue":"19","key":"10.1016\/j.vaccine.2023.02.057_b0165","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2004.08.049","article-title":"Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations","volume":"23","author":"Miles","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.057_b0170","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0264-410X(96)00150-8","article-title":"Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720","volume":"15","author":"Lawrence","year":"1997","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.057_b0175","doi-asserted-by":"crossref","first-page":"e0262162","DOI":"10.1371\/journal.pone.0262162","article-title":"IgG3 and IgM identified as key to SARS-CoV-2 neutralization in convalescent plasma pools","volume":"17","author":"Kober","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2023.02.057_b0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.02.057_b0185","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2202061","article-title":"Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa","author":"Gray","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2023.02.057_b0190","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMc2119641","article-title":"Plasma neutralization of the SARS-CoV-2 Omicron variant","volume":"386","author":"Schmidt","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.057_b0195","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1002\/ctm2.839","article-title":"Understanding Omicron: transmissibility, immune evasion and antiviral intervention","volume":"12","author":"Hoffmann","year":"2022","journal-title":"Clin Transl Med"},{"issue":"19","key":"10.1016\/j.vaccine.2023.02.057_b0200","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.02.057_b0205","first-page":"1","article-title":"COVID-19 vaccine booster strategies for Omicron SARS-CoV-2 variant: effectiveness and future prospects","volume":"10","author":"Zarebska-Michaluk","year":"2022","journal-title":"Vaccines (MDPI)"},{"issue":"8","key":"10.1016\/j.vaccine.2023.02.057_b0210","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1017\/ice.2021.199","article-title":"\u201cOriginal antigenic sin\u201d: a potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants","volume":"43","author":"Noori","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"10.1016\/j.vaccine.2023.02.057_b0215","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157707","article-title":"A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants","volume":"132","author":"Wang","year":"2022","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.057_b0220","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.057_b0225","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/s41467-022-30162-5","article-title":"Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants","volume":"13","author":"Belik","year":"2022","journal-title":"Nat Commun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:05Z","timestamp":1759404245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":45,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23002001"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase I\/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}